NeuroOne Appoints David Wambeke as Chief Business Officer with Concurrent Share Purchase

NeuroOne Medical Technologies Corporation announced the appointment of David Wambeke as Chief Business Officer, accompanied by his personal purchase of 1,000,000 shares of company common stock. This dual announcement represents both a strategic leadership addition and a significant vote of confidence in the medical technology company's direction. Wambeke will lead NeuroOne's drug delivery program while working closely with the executive team to advance clinical development and commercialization strategies. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders in targeted disease areas, and engaging prospective pharmaceutical partners to maximize the strategic value of the company's emerging drug delivery platform.

The appointment brings substantial healthcare and capital markets expertise to NeuroOne at a critical juncture in the company's expansion. Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia, establishing and overseeing a first-in-pregnancy Phase 2 clinical trial that delivered positive results and contributed to substantial shareholder value creation. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, mergers and acquisitions, and strategic transactions. NeuroOne CEO Dave Rosa emphasized that Wambeke brings "a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution."

Wambeke's concurrent purchase of 1,000,000 shares at $0.6704 per share represents a tangible alignment with shareholders and signals strong conviction in NeuroOne's strategic growth trajectory. The company intends to use the net proceeds from this sale to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. This insider investment occurs as NeuroOne continues to scale commercialization across its four FDA 510(k)-cleared devices and builds upon its strategic partnership with Zimmer Biomet. Wambeke noted that "with four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications."

The strategic importance of this appointment extends beyond immediate leadership capabilities to encompass broader market implications. Wambeke will also oversee investor relations, strengthening the company's market communication and broadening engagement with the investment community while supporting strategic business development initiatives including partnerships and other corporate transactions. This comes at what Wambeke describes as "a pivotal moment" for the company as it explores opportunities in basivertebral ablation, drug delivery, and spinal cord stimulation. The company's technology platform, detailed at https://nmtc1.com, includes minimally invasive and high-definition/high-precision electrode technology with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain, and OneRF Trigeminal Nerve Ablation System.

In connection with Wambeke's appointment, NeuroOne granted him an inducement stock option to purchase 500,000 shares of common stock pursuant to the NeuroOne Medical Technologies Corporation 2021 Inducement Plan. This inducement grant was approved by the company's compensation committee and was a material inducement to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $0.6704 per share, equal to the closing price of NeuroOne's common stock on the grant date, with a 10-year term and vesting over four years. This comprehensive compensation package, combined with the substantial personal investment, underscores the mutual commitment between the executive and the company during a period of strategic expansion in neurological disorder treatments.